Since 2014, enterovirus D68 has emerged as a recurring threat to child health, establishing a pattern of biennial outbreaks across the United States. The virus achieved particular notoriety in 2016 when it triggered a peak in acute flaccid myelitis cases—a polio-like paralysis condition. Now, emerging vaccine research offers a data-driven response to this epidemiological challenge.
A new preclinical study published in Science Translational Medicine demonstrates that a virus-like particle vaccine successfully generates neutralizing antibodies against EV-D68 in primate models. The vaccine specifically targets receptor binding sites on the viral surface that are critical for infection establishment. By blocking these attachment points, neutralizing antibodies prevent the virus from entering host cells—a fundamental mechanism of immune protection. With documented surveillance data showing consistent outbreak cycles, this vaccine candidate represents a potentially transformative intervention for reducing both respiratory illness burden and the neurological complications that distinguish EV-D68 from other enteroviral infections.
Read the full article on GMJ Newsroom.
Was this article helpful?
